| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Jun 2025 | 11 Jun 2025 |
| Please find enclosed outcome of the Board Meeting | ||
| Board Meeting | 19 May 2025 | 13 May 2025 |
| Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve Audited Standalone & Consolidated Financial Results of the Company for the Fourth Quarter and Year ended March 31 2025 Please find enclosed Outcome of the Board Meeting (As Per BSE Announcement Dated on: 19/05/2025) | ||
| Board Meeting | 9 Jan 2025 | 2 Jan 2025 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/01/2025 inter alia to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2024. Outcome of the Board Meeting Issue of Securities (As Per Bse Announcement Dated on 09.01.2025) | ||
| Board Meeting | 21 Nov 2024 | 15 Nov 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/11/2024 inter alia to consider and approve the Vivo Bio Employees Stock Option Scheme 2024 (VBESOS 2024) in terms of SEBI (Share Based Employee Benefits and Sweat Equity) regulations 2021. With reference to the above cited subject and our letter dated November 15, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Thursday, November 21, 2024, inter-alia, transacted the following business: 1. Pursuant to the recommendations of the Nomination and Remuneration Committee (NRC), approved the Vivo Bio Employees Stock Option Scheme, 2024 (VBESOS, 2024) for grant of stock options to eligible Directors and Employees of the Company and its Group Company(ies) including its Subsidiary / Associate Company(ies) (Present and Future, if any), subject to approval of the shareholders of the Company, as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 [SEBI (SBEBSE) Regulations, 2021]. The Company shall seek the approval of Members through postal ballot (As per BSE Announcement Dated on 21/11/2024) | ||
| Board Meeting | 14 Nov 2024 | 29 Oct 2024 |
| Quarterly Results Please find enclosed Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024 (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 26 Aug 2024 | 26 Aug 2024 |
| Please find enclosed Outcome of the Board Meeting | ||
| Board Meeting | 10 Aug 2024 | 1 Aug 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2024. Please find enclosed Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 10/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.